Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

British Journal of Cancer

Volumn 77, Issue 8, 1998, Pages 1355-1362

  Bokemeyer, C ^a,d   Berger, C C ^a   Hartmann, J T ^a   Kollmannsberger, C ^a   Schmoll, H J ^b   Kuczyk, M A ^c   Kanz, L ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Long term toxicity; Ototoxicity; Testicular cancer

Indexed keywords

CISPLATIN; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; HEARING LOSS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NOISE; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RISK FACTOR; TESTIS CANCER; TINNITUS;

EID: 0031885884     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.226     Document Type: Article

References (48)

1. Aass N, Kaasa S, Lund E, Kaalhus O, Skard Heier M and Fossa SD (1990) Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer 61: 151-155
2. Aguilar-Markulis NV, Beckley S, Priore R and Mettlin C (1981) Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 16: 111-123
3. Bissett D, Kunkeler L, Zwanenburg L, Paul J, Gray C, Swan IRC, Kerr DJ and Kaye SB (1990) Long-term sequelae of treatment for testicular germ cell tumour. Br J Cancer 62: 655-659
4. Black FO, Myers EN and Schramm VL (1982) Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope 92: 1363-1368
5. Blakley BW, Gupta AK, Myers SF and Schwan S (1994) Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 120: 541-546
6. Bokemeyer C (1997) Current trends in the chemotherapy for non-seminomatous metastatic testicular germ cell tumours. Oncnlogy (in press)
7. Bokemeyer C, Berger CC, Kuczyk MA and Schmoll H-J (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923-2932
8. Bosl JG and Motzer RJ (1997) Testicular germ-cell cancer. New Engl J Med 337: 242-253
9. Boyer M, Raghavan D, Harris PJ, Lietch J, Bleasel A, Walsh JC, Anderson S and Tsang C-S (1990) Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8: 21-26
10. Brock P (1991) Ototoxicity of cisplatinum. Br J Cancer 63: 159
11. Church MW, Kaltenbach JA, Blakley BW and Burgio DL (1995) The comparative effects of sodium thiosulfale, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res 86: 195-203
12. Dolev E, Tamir A and Leventon G (1983) Is magnesium depletion the reason for ototoxicity caused by aminoglycosides? Med Hypotheses 10: 353-358
13. Domenech J, Carulla M and Traserra J (1990) Tinnitus in the diagnosis and prognosis of ototoxicity. Acta Otorrinolaringol Esp 41: 7-9
14. Dreshler WA, Van Der Hulst RJAM, Tange RA and Urbanus NAM (1985) The role of high-frequency audiometry in early detection of ototoxicity. Audiology 24: 387-395
15. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS and Fowler CG (1994) High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 15: 232-239
16. Fossa SD, Aass N, Kaalhus O, Klepp O and Tveter K (1986) Long-term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy. Cancer 58: 2600-2605
17. Gratton MA, Salvi RJ, Kamen BA and Saunders SS (1990) Interaction of cisplatin and noise on the peripheral auditory system. Hear Res 50: 211-223
18. Gunther T, Rebentisch E, Vormann J, König M and Ising H (1988) Enhanced ototoxicity of gentamycin and salicylate caused by Mg deficiency and Zn deficiency. Biol Trace Elem Res 16: 43-50
19. Hallmark RJ, Snyder JM, Jusenius K and Tamini HK (1992) Factors influencing ototoxicity in ovarian cancer patients treated with cisplatin based chemotherapy. Eur J Gynaecol Oncol 13: 35-43
20. Hansen SW (1992) Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan Med Bull 39: 391-399
21. Hartwig S, Pettersson U and Stahle J (1983) Cis-diamminedichloroplatinum: a cytostatic with an ototoxic effect. ORL 45: 257-261
22. Helson L, Okonkwo E, Anton L and Cvitkovic E (1978) Cis-platinum ototoxicity. Clin Toxicol 13: 469-478
23. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D and Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112
24. Laurell GFE (1992) Combined effects of noise and cisplatin: short- and long-term follow-up. Ann Otol Rhinol Laryngol 101: 969-976
25. Lautermann J, Song B, McLaren J and Schacht J (1995) Diet is a risk factor in cisplatin ototoxicity. Hear Res 88: 47-53
26. Lehnhardi E (1978) Praktische Audiometrie. 5. Aufl. Georg Thieme: Stuttgart
27. Marco-Algarra J, Basterra J and Marco J (1985) Cis-diaminedichloroplatinum ototoxicity. Acta Otolaryngol 99: 343-347
28. McAlpine D and Johnstone BM (1990) The ototoxic mechanism of cisplatin. Hear Res 47: 191-204
29. Melamed LB, Selim MA, Facs F and Schuchman D (1985) Cisplatin ototoxicity in gynecologic cancer patients. Cancer 55: 41-43
30. Moul JW, Robertson JE, George SL, Paulson DF and Walther PJ (1989) Complications of chemotherapy for testicular cancer. J Urol 142: 1491-1496
31. Nakai Y, Konishi K, Chang KC, Ohashi K, Moriaski N, Minowa Y and Morimoto A (1982) Ototoxicity of the anticancer drug cisplatin. Acta Otolaryngol 93: 227-232
32. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JAPM and Hermans J (1992) Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10: 574-579
33. Piel IJ, Meyer D, Perlia CP and Wolfe VI (1974) Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 58: 871-875
34. Ravi R, Somani SM and Rybak LP (1995) Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76: 386-394
35. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM and Tattersall MHN (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer 66: 19-23
36. Riggs LC, Brummett RE, Guitjens SK and Matz GJ (1996). Ototoxicity resulting from combined administration of cisplatin and gentamycin. Laryngoscope 106: 401-406
37. Rybak LP, Ravi R and Somani SM (1995) Mechanisms of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol 26: 293-300
38. Saito T and Aran JM (1994) Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL J 56: 315-320
39. Schaefer SD, Post JD, Close LG and Wright CG (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 1934-1939
40. Schilsky RL (1982) Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 9: 75-81
41. Schwabe H-R, Herrmann R, Mathew M, Graef K-J, Sander T, Cordes M, Nagel R, Weissbach L and Huhn D (1992) Langfristige Toxizität der Polychemotherapie bei kurativ behandeltem Hodenkarzinom. Dtsch Med Wschr 117: 121-126
42. Schweitzer VG (1993) Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 26: 759-789
43. Skinner R, Pearson ADJ, Amineddine HA, Mathias DB and Craft AW (1990) Ototoxicity of cisplatin in children and adolescents. Hr J Cancer 61: 927-931
44. Stoter G, Koopman A, Vendrik CPJ, Struyvenberg A, Sleyfer DT, Willemse PHB, Schraffordt Koops H, Van Oosterom AT, Ten Bokkel Huinink WW and Pinedo HM (1989) Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 7: 1099-1104
45. Stuart NSA, Woodroffe CM, Grundy R and Cullen MH (1990) Long-term toxicity of chemotherapy for testicular cancer - the cost of cure. Br J Cancer 61: 479-484
46. Van Der Hulst RJAM, Dreshler WA and Urbanus NAM (1988) High-frequency audiometry in prospective clinical research of ototoxicity due to platinum derivates. Ann Otol Rhinol Laryngol 97: 133-137
47. Vermorken JB, Kapteijn TS, Hart AAM and Pinedo HM (1983) Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19: 53-58
48. Waters GS, Ahmad M, Katsarkas A, Stanimir G and McKay J (1991) Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 12: 91-102